Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

2
Pfizer Raises Prices of 40 Drugs, Some by Nearly 10%

2018-07-03 biospace
In May President Donald Trump predicted a “massive drops” in drug prices following the signing of the Right-to-Try legislation, as well as a Health and Human Services initiative he called “the most sweeping action in history” to lower the cost of prescription drug prices.
GCVRZ SAN SNYNF SNY

135
Mylan Stock Looks Cheap, but Don’t Overlook These Risks

2018-06-21 investorplace
Mylan N.V. (NASDAQ:MYL) has been a battleground stock in 2018. And that’s with good reason, Mylan stock has seen plenty of good news, but also a number of setbacks. EpiPen is a perfect example. The brand brought Mylan shame and a substantial fine, but it’s also in short supply now, continuing to lead to strong ongoing profits.
MYL TEVJF GCVRZ TEVA TEVVF SAN SNYNF GSK SNY

109
3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry

2018-06-14 investorplace
In spite of a strong start in 2018, the pharma/biotech industry is struggling currently, presumably due to a shift in focus to lowering of high drug prices and faster approval of generics. Moreover, quite a few negative pipeline and regulatory updates announced this year so far have probably had an unfavorable impact on the industry.
CELGZ AZN IPXL GSK SNY SHPG MRK GCVRZ CELG NVS SAN SNYNF

70
5 Biotech Stocks to Boost Your Portfolio’s Health This Year

2018-05-31 investorplace
Though the drug sector was off to a strong start in 2018, it has struggled thereafter probably on U.S. market instability and a few negative updates on the pipeline and regulatory front. Also, a slowdown in sales of some of the most high-profile older drugs, courtesy of payers and competitive pressure from both branded and generic drugs, is a concern for the sector. Moreover, concerns about pressure on drug prices continue to cloud shares of pharma and biotech companies.
CELGZ IPXL GCVRZ CELG CRSP SAN SNYNF SNY AMRX

28
Pfizer Inc. Is Stuck in a Trading Range – for Now

2018-05-03 investorplace
Still stuck in a trading range, Pfizer Inc. (NYSE:PFE) may continue to drift in either direction after its quarterly earnings report supplied no near-term catalysts. Revenue growing just a percent from last year is uninspiring, while some of the smaller units, like Oncology and Rare Diseases, showed some growth. Pfizer’s drug Viagra coming off patent protection is still the biggest headwind for PFE stock at the moment.
REGN PFZ GCVRZ SAN 500680 SNYNF PFE PFIZER SNY ESRX

15
Regeneron Pharmaceuticals (REGN) Q1 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
Welcome to the Regeneron Pharmaceuticals First Quarter 2018 Earnings Conference Call. My name is Jason and I will be your operator. At this time all participants will be in a listen-only mode. Later, we will have a question-and-answer session. Also, please note this conference is being recorded.
MTZXF REGN MTZPY GCVRZ SAN SNYNF 4508 SNY

13
UPDATE 3-Regeneron/Sanofi cut heart drug price to $4,500-$6,600 for Express Scripts

2018-05-01 reuters
(Reuters) - Regeneron Pharmaceuticals Inc and Sanofi SA will slash the price of their expensive cholesterol drug for Express Scripts Holdings Co customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.
REGN GCVRZ SAN CVS SNYNF SNY

0
Regeneron, Sanofi chop cholesterol drug price in Express Scripts pact

2018-05-01 cnbc
Sanofi and Regeneron have agreed to lower the price of their cholesterol medicine in exchange for easier access for patients covered by pharmacy benefit manager Express Scripts, the first of a number of deals the drugmakers hope to strike to increase use of the medicine.
GCVRZ SAN SNYNF SNY

0
Regeneron and Sanofi Eye October for FDA Review of Skin Cancer Drug Cemiplimab

2018-04-30 biospace
Regeneron and its longtime development partner Sanofi are keeping their proverbial fingers crossed that their profitable collaboration will yield yet another approved treatment this year.
GCVRZ SAN SNYNF SNY

0
Sanofi SA Shares Slip on Falling Sales

2018-04-27 investorplace
Sanofi SA (ADR) (NYSE:SNY) stock was down Friday on disappointing sales reported in the first quarter of 2018.
GCVRZ SAN SNYNF SNY

0
Sanofi SA (SNY) Fundamental Valuation Report

2018-04-26 valuewalk
This Report was generated using the tools available on StockCalc.com. Patchell Brook Equity Analytics Inc. emphasizes that the user assumes all risks associated with the use of this report or the Stockcalc website including, but not limited to, all terms and conditions mentioned in the legal disclaimer. To access all of the tools on Stockcalc, including more detailed valuation reports and the models used to generate these valuations, please subscribe for a free 30 day trial of Stockcalc here.
GCVRZ SAN SNYNF SNY

87
PRESS DIGEST- Financial Times - April 16

2018-04-16 reuters
April 16 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.
BCS.PRD BCS BCS.PRC BCS.PRA GS.PRB GS.PRA 83SF GS GLSSP 83SK GCVRZ 47MC JBK GSC GS.PRICL TFG GSJ SNY GS.PRJ GS.PRI BCS.PR GS.PRD GS.PRC SAN GJS SNYNF GS.PRN GS.PRK

13
What Lies Ahead for France ETFs?

2018-04-13 zacks
The French economy grew slower than estimated, per the Bank of France, primarily owing to a slowdown in manufacturing activity. The bank’s lower growth estimate for the first quarter is indicative of a somewhat broader slowdown in the Euro zone. European Central Bank (ECB) Executive Board member Benoit Coeure thinks the Euro bloc is witnessing a correction rather than a slowdown, per a Reuters article.
FP BNC GD GCVRZ MBUU SANT SAN SNYNF SAN SNY

54
European Buyers Go Shopping for U.S. Companies - WSJ

2018-04-07 wsj
European executives are targeting U.S. companies as a brighter economic landscape at home and abroad boosts buyer confidence.
AXAHF CS XL AXJ HSB AXAHY UBS GCVRZ UBS.PRDCL HSBC.PRA HSBC HBCYF HCS.PRB SKG HCS BIVV SNY 0005 HSEA TRI HSEB XLGLF SAN SMFKY QCOM SNYNF ULSGF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to EPA:SAN / SANOFI on message board site Silicon Investor.

Sandstorm Gold Margaret Sangeru0027s Eugenic Legacy of Death, Disease, Depravit
Monsanto (MON) : Valuation and Ethics of BioEngineering WDC/Sandisk Corporation
Sangamo BioSciences, Inc. SGMO Bernie Sanders 2016
Las Vegas Sands Corp. (LVS) Bernie Sanders Comedy Message Board 2016
Bill Clinton Scandal - SANITY CHECK CLL oilsands play